aztreonam has been researched along with Cough in 2 studies
Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.
Cough: A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions, or to prevent aspiration of foreign materials into the lungs.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Baseline bronchitic symptoms predict response to inhaled aztreonam in bronchiectasis." | 7.96 | Inhaled aztreonam improves symptoms of cough and sputum production in patients with bronchiectasis: a ( Barker, AF; Chalmers, JD; Crichton, ML; Goeminne, P; Lonergan, M; Shoemark, A; Sibila, O, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Crichton, ML | 1 |
| Lonergan, M | 1 |
| Barker, AF | 2 |
| Sibila, O | 1 |
| Goeminne, P | 1 |
| Shoemark, A | 1 |
| Chalmers, JD | 1 |
| O'Donnell, AE | 1 |
| Flume, P | 1 |
| Thompson, PJ | 1 |
| Ruzi, JD | 1 |
| de Gracia, J | 1 |
| Boersma, WG | 1 |
| De Soyza, A | 1 |
| Shao, L | 1 |
| Zhang, J | 1 |
| Haas, L | 1 |
| Lewis, SA | 1 |
| Leitzinger, S | 1 |
| Montgomery, AB | 1 |
| McKevitt, MT | 1 |
| Gossage, D | 1 |
| Quittner, AL | 1 |
| O'Riordan, TG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution in Subjects With Non-CF Bronchiectasis and Gram-Negative Endobronchial Infection[NCT01313624] | Phase 3 | 266 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution/Aztreonam 75 mg Powder and Solvent for Nebuliser Solution in Subjects With Non-CF Bronchiectasis and Gram-Negative [NCT01314716] | Phase 3 | 274 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The mean (SD) change in the Respiratory Symptoms score on the Quality of Life Questionnaire-Bronchiectasis (QOL-B) was measured from baseline to the end of Course 1 (Day 28). The QOL-B respiratory symptoms score was transformed onto a scale of 0-100, with higher scores representing a better quality of life. (NCT01313624)
Timeframe: Baseline to Day 28
| Intervention | units on a scale (Mean) |
|---|---|
| AZLI-AZLI | 7.4 |
| Placebo-AZLI | 5.7 |
The mean (SD) change in the Respiratory Symptoms score on the QOL-B was measured from baseline to the end of Course 2 (Day 84). The QOL-B respiratory symptoms score was transformed onto a scale of 0-100, with higher scores representing a better quality of life. (NCT01313624)
Timeframe: Baseline to Day 84
| Intervention | units on a scale (Mean) |
|---|---|
| AZLI-AZLI | 7.4 |
| Placebo-AZLI | 4.7 |
"Protocol-defined exacerbation was defined as an acute worsening of respiratory disease that triggered the initiation of a non-study antibiotic meeting at least 3 major criteria, or 2 major and at least 2 minor criteria.~Major Criteria: increased sputum production; increased discoloration of sputum; increased dyspnea; increased cough~Minor Criteria: fever (> 38º C) measured during clinic visit; increased malaise or fatigue; forced expiratory volume in 1 second (FEV1) (L) or forced vital capacity (FVC) decreased > 10% from baseline; new or increased hemoptysis" (NCT01313624)
Timeframe: Baseline to Day 112
| Intervention | days (Median) |
|---|---|
| AZLI-AZLI | NA |
| Placebo-AZLI | 120 |
The mean (SD) change in the Respiratory Symptoms score on the Quality of Life Questionnaire-Bronchiectasis (QOL-B) was measured from baseline to the end of Course 1 (Day 28). The QOL-B respiratory symptoms score was transformed onto a scale of 0-100, with higher scores representing a better quality of life. (NCT01314716)
Timeframe: Baseline to Day 28
| Intervention | units on a scale (Mean) |
|---|---|
| AZLI-AZLI | 8.2 |
| Placebo-AZLI | 3.2 |
The mean (SD) change in the Respiratory Symptoms score on the QOL-B was measured from baseline to the end of Course 2 (Day 84). The QOL-B respiratory symptoms score was transformed onto a scale of 0-100, with higher scores representing a better quality of life. (NCT01314716)
Timeframe: Baseline to Day 84
| Intervention | units on a scale (Mean) |
|---|---|
| AZLI-AZLI | 5.6 |
| Placebo-AZLI | 3.9 |
"Protocol-defined exacerbation was defined as an acute worsening of respiratory disease that triggered the initiation of a non-study antibiotic meeting at least 3 major criteria, or 2 major and at least 2 minor criteria.~Major Criteria: increased sputum production; increased discoloration of sputum; increased dyspnea; increased cough~Minor Criteria: fever (> 38º C) measured during clinic visit; increased malaise or fatigue; forced expiratory volume in 1 second (FEV1) (L) or forced vital capacity (FVC) decreased > 10% from baseline; new or increased hemoptysis" (NCT01314716)
Timeframe: Baseline to Day 112
| Intervention | days (Median) |
|---|---|
| AZLI-AZLI | NA |
| Placebo-AZLI | NA |
1 trial available for aztreonam and Cough
| Article | Year |
|---|---|
Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aztre | 2014 |
Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aztre | 2014 |
Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aztre | 2014 |
Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aztre | 2014 |
1 other study available for aztreonam and Cough
| Article | Year |
|---|---|
Inhaled aztreonam improves symptoms of cough and sputum production in patients with bronchiectasis: a
Topics: Administration, Inhalation; Anti-Bacterial Agents; Aztreonam; Bronchiectasis; Cough; Humans; Quality | 2020 |